endometriosis case study cultiva.

JEALOUSY THG24 INDICA-DOMINANT



AT A GLANCE

Effective Dose

Cultiva Jealousy THC24 0.2g PRN (0.6g daily)

CBD Full Spectrum 100mg/ml 0.8ml BD (160mg daily)

THC Dominant Oil 20mg/ml 0.4ml nocte (8mg nocte)

Method of Administration

Inhalation, Storz & Bickel Mighty Medic (TGA-approved vaporiser)

Patient Outcomes

- Notable reduction in pelvic pain
- Improvement in sleep quality
- Reduction in use of opioid medications
- Reduction in anxiety symptoms
- Enhanced mood and optimism
- Increased engagement in social activities and improved overall quality of life

PATIENT PROFILE

Age 32 Sex Female

Presenting Diagnosis

Endometriosis

History

Affected by condition since teenage years
Severe pelvic pain around time of
menstruation and ovulation
Pain during or after intercourse
Excessive bleeding at time of menstruation
Ongoing GI disturbances: painful defecation,
constipation and loose bowel motions

Presenting Symptoms

Chronic pelvic pain Menorrhagia Dysmenorrhea Dyspareunia Fatigue Anhedonia

Impact on Life

Pain largely impacting emotional wellbeing and mood Decreased daily functional and occupational capacity Affects interpersonal relationships

Comoborbidities

Generalised Anxiety Disorder (GAD) Depression

Current Therapies

Paracetamol/Codeine 500mg/30mg PRN
Oxycodone 5mg PRN
Mirena IUD
Ongoing Psychologist Consultation
Remedial Massage PRN
Pelvic Floor Physiotherapy

Previous Therapies

Naproxen 275mg PRN OCP Hormonal Birth Control Laparoscopic Surgery x2 Psychologist endometriosis case study cultiva.

TREATMENT PLAN

Week 01

Cultiva Jealousy THC24 0.1g PRN (0.3g daily)

CBD Full Spectrum 100mg/ml 0.2ml BD (40mg daily)

THC Dominant Oil 20mg/ml 0.2ml nocte (4mg nocte)

Reported slight reduction in pelvic pain and improved sleep quality. No adverse effects noted.

Week 02

Cultiva Jealousy THC24 0.1g PRN (0.4g daily)

CBD Full Spectrum 100mg/ml 0.4ml BD (80mg daily)

THC Dominant Oil 20mg/ml 0.4ml nocte (8mg nocte)

Noted reduction in daily pain severity and enhancement in sleep quality.

Noted improvement in baseline anxiety symptoms. 50% reduction in utilisation of PRN Paracetamol/Codeine and Oxycodone. Reported improvement in sleep onset and maintenance.

Week 03

Cultiva Jealousy THC24 0.2g PRN (0.4g daily)

CBD Full Spectrum 100mg/ml 0.6ml BD (120mg daily)

THC Dominant Oil 20mg/ml 0.4ml nocte (8mg nocte)

Patient reported improvement in gastrointestinal symptoms including reduction of constipation due to reduced Paracetamol/ Codeine utilisation. Resumed gradual introduction of exercise program including pelvic floor physio and pilates therapies. Noted reduction in pain at time of ovulation. Sustained improvement in sleep quality resulting in mood enhancement and reduction of anxiety symptoms.

Week 04

Cultiva Jealousy THC24 0.2g PRN (0.6g daily)

CBD Full Spectrum 100mg/ml 0.8ml BD (160mg daily)

THC Dominant Oil 20mg/ml 0.4ml nocte (8mg nocte) Reported overall significant pelvic pain reduction, allowing engagement in daily activities with greater ease and comfort. Mood continues to improve, and the patient reports feeling more optimistic about condition and future outlook. Sleep quality remains stable, contributing to overall improvements in energy and vitality.

PATIENT OUTCOMES

Effect on Symptoms

- Progressive reduction in pelvic pain, with initial slight improvement followed by notable reductions in pain severity in subsequent weeks.
- Improvement in sleep quality.
- Reduction of PRN opioid medications.

Effect on Daily Life

- Enhanced mood, increased optimism, and improved overall quality of life.
- Allowed patient to engage in daily activities with greater ease and comfort.

Patient Satisfaction

- Patient expressed high satisfaction with the treatment outcomes.
- Patient found inhalation method particularly beneficial for acute symptom management.
- Patient felt empowered to engage in activities that were previously limited by pain and expressed gratitude for the significant improvement in her quality of life.

Doctor's Note

- Patient responded positively to treatment, experiencing a progressive improvement in symptoms and quality of life.
- Initially, there was a slight reduction in pelvic pain and improved sleep quality, with no adverse effects noted.
- This was followed by a notable reduction in daily pain severity, enhanced sleep, and improved anxiety symptoms.
- Patient also reported a 50% reduction in the use of PRN Paracetamol/Codeine and Oxycodone.
- Patient reported a significant reduction in daily pelvic pain, allowing for greater ease and comfort in engaging in daily activities.
- Mood continued to improve, with the patient feeling more optimistic about their condition and future outlook.
- Overall, the treatment had a positive impact on the patient's symptoms and quality of life, with continued monitoring recommended to assess long-term efficacy and safety.